BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Bio firm Celltrion wins domestic approval to sell Remsima SC

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : Febuary 27, 2020, 12:39 | Updated : Febuary 27, 2020, 12:39
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]

SEOUL -- Celltrion, a bio firm in South Korea, has won domestic approval to sell Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease.

Celltrion said that the Ministry of Food and Drug Safety, a South Korean government health agency, has approved Remsima SC's efficacy in rheumatoid arthritis. Celltrion will seek additional approval for Remsima SC's efficacy in inflammatory bowel disease.

The target of Remsima SC is patients who are forced to move on to expensive secondary treatments due to resistance. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject Remsima SC into the fat layer beneath the skin at home.

In November 2019, Celltrion acquired final approval to sell Remsima SC in Europe. The company plans to acquire U.S. approval in 2022.

With Remsima SC, Celltrion has adopted an aggressive strategy to secure profitability and price penetration in competition with other subcutaneous-type products such as Adalimumab, sold under the brand name of Humira, which is on the World Health Organization's List of essential medicines.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .State watchdog starts screening Celltrions antibody treatment for COVID-19.
    State watchdog starts screening Celltrion's antibody treatme…
  • .Celltrion leaves door open for consignment production of COVID-19 vaccines.
    Celltrion leaves door open for consignment production of COV…
  • .GC Pharmas plasma treatment allowed for actual use in treating COVID-19 patients.
    GC Pharma's plasma treatment allowed for actual use in treat…
  • . Celltrion revises deal with U.S. client to ship new rapid COVID-19 antigen test kit.
    Celltrion revises deal with U.S. client to ship new rapid C…
  • .  Celltrion checks antibody treatments effect of COVID-19 infection prevention    .
    Celltrion checks antibody treatment's effect of COVID-19 i…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • Samsung to release Galaxy SmartTag tracker for keys and pets
  • Hanmi Pharmaceutical unveils quick COVID-19 antigen test kit
  • Hyundai Wia develops efficient heat management module for electric vehicles
  • ​S. Korean convenience store chain releases 'Doenjang' DIY kit for homebodies
  • Singer IU drops teaser image for upcoming full album
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view